Loading company…
Septerna discovers medicines targeting G protein-coupled receptors across several therapeutic areas.
Founded in 2019 and based in California, US, Septerna uses a platform to discover medicines targeting G protein-coupled receptors, with programs in endocrine, CNS, and inflammation. In October 2024, it raised USD 288 million in an IPO, selling 16 million shares at USD 18 per share on the Nasdaq Global Select Market under ticker SEPN. Third Rock Ventures retained a 20.8% stake and RA Capital retained a 6.7% stake.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in